Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017
Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.
You may also be interested in...
With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.
Third enforcement letter of the year cites meeting exhibit and webpage that suggest crenolanib is safe and effective for an unapproved use.
Agency objects to video interview in which Pfizer spokespeople fail to mention risks of estradiol vaginal ring, in OPDP's second enforcement letter of the year.